We now suggest extending life through licardin, and then look for further treatment opportunities!
The following information is for your reference.
The Fourth Military Medical University independently developed targeted drugs for liver cancer.
2007 65438+February 65438+July 17: 25: 49 Source: Xinhuanet.
Xinhua Net An 65438+February 17 (Reporter Xu Zuhua, Ding Haitao) The reporter learned from the Fourth Military Medical University on June 17 that the school independently developed a specific antibody targeting drug for the treatment of liver cancer-I [13 1I] Metuximab injection.
This drug was developed by a research team led by Professor Chen Zhinan, director of the Cell Engineering Research Center of the Fourth Military Medical University for 20 years. According to clinical experts, licatin was solved for the first time.
The preparation technology of fragment antibody makes the targeting vector easily penetrate into cancer tissues, and at the same time solves the disadvantages of causing antibody immune response. It can be used as a first-line therapeutic drug for various stages of liver cancer or as a combination of radiotherapy and chemotherapy.
According to the annual health report of the World Health Organization, 620,000 people worldwide die of liver cancer every year.
/News Center/2007-12/17/content _ 7268261.htm
After interventional therapy of liver cancer.
Hello, doctor! My father found that he has been involved in tumor control for three times now, and AFP has dropped from the original 1000 to the present 9. Liver function is fine, and now ALT 58, AST5 1, bilirubin and protein are normal. It's just that GGT 288 and ALP 180 are a little high, their faces are a little dark and their pores are a little big. It seems that the detoxification function of liver is not good? Is there any way to reduce GGT and ALP? Improve your face? thank you
Hello, because the experts of liver cancer group have gone abroad to attend academic conferences, I am very sorry to reply to your message now. I don't know if you made Likatine in our hospital. If so, you can tell me your name. We can pull up your father's medical records and answer your questions according to the specific situation. Is it possible?
Release date of sender's consultation: March 2008-14
-Transferred from the website of the 458th Medical College of China People's Liberation Army (in Guangdong)/index.asp.
It's a pity that my cousin who works in Guangzhou can't use Likatine. Last June, he was ruthlessly killed by liver cancer, which made his family and our people very sad, because he was also a modest official and our pride. According to the data of your hospital, it should have been more than 6 months since the first batch of patients in your hospital used Likatine. What's their situation now? How many of them are still alive? What is the survival rate? Did someone get a second shot? I really hope you can tell the expectant patients as soon as possible! thank you
Hello, generally speaking, the average survival time of patients diagnosed with liver cancer is 4.2 months, and the median survival time of patients after using licardin is more than 19 months. More than 80 patients with liver cancer were treated with licardin in our center, and the effective rate was over 60%. Likatine can be injected with 1-6 needles. Up to now, more than ten people in our center have received the second injection, and five patients have received the third injection. Compared with traditional chemotherapy drugs, licardin has basically no side effects, and occasionally has a short-term low fever and rash. High security.
Published by the sender jyx on March 4th, 2008.
-Transferred from the website of the 458th Medical College of China People's Liberation Army (in Guangdong)/index.asp.
Likatine, the world's first monoclonal antibody-directed drug for the treatment of primary liver cancer, also owns all intellectual property rights.
Double-effect integration: Metuximab blocked the proliferation and metastasis of hepatocellular carcinoma cell antigen Hab 18G/CD 147.
Iodine [13 1I] emits beta rays to kill liver cancer cells.
-Transferred from Chengdu Huashen Biotechnology Co., Ltd..
Likatine, the world's first monoclonal antibody drug to treat primary liver cancer.
Likatine, an iodine [13 1i] metuximab injection project, was developed by the Fourth Military Medical University of PLA for 20 years. Likatine was supported by the National Eighth Five-Year Plan, the Ninth Five-Year Plan, the Tenth Five-Year Plan, the National 863 Program and the National 1035 Project, and was awarded 1999.
The product creatively takes the fragment of Metuximab as the guiding carrier, selectively and pertinently brings the radionuclide 13 1I to the liver cancer site, and effectively kills the cancer cells by using the B-rays emitted by it, while no radiopharmaceuticals accumulate in other organs of the whole body, thus providing a brand-new treatment method with great clinical application value for the "king of human cancer"-liver cancer.
This product technology has been declared and obtained many international and domestic patents:
At present, the project has completed the basic construction, obtained the production license and production approval, and recently completed the GMP certification application.
Clinical application of iodine [13 1i] metuximab injection;
Patients with liver cancer-take blood samples-send them to Huashen Company for culture of metuximab-set the dosage for patients-/kloc-airlift antibodies within 0/2 hours-label them with radionuclide 13 1I synthesized by Beijing (China Nuclear Power Research Institute)-send them to the patient's hospital within 24 hours-12 hours for injection into patients.
Introduction of the course of treatment of Metuximab injection;
Metuximab injection is injected twice as a course of treatment, and one year as a course of treatment.
Observation on the curative effect of Metuximab injection;
According to the report of the third phase clinical trial of Metuximab Injection by the State Food and Drug Administration, the number of people in the third phase clinical trial was 100, and the total course of treatment was * * *.
Results 1: After the injection of Metuximab, all patients' physical pain was obviously relieved, and their quality of life and consciousness were obviously improved.
Effect 2: In the experiment, the number of patients injected with Metuximab decreased significantly from 6 cm- 16 cm to 2 cm-4 cm, and they were patients.
Support surgical treatment, create new conditions, and greatly improve the survival probability of patients.
Effect 3: Patients injected with Metuximab did not find any signs of cancer cell spread.
Effect 4: After stopping taking drugs in 2004, cancer cells in 2 patients completely disappeared, 28 patients were still alive, 38 people were unaccounted for (lost contact with the hospital), and the life expectancy of the dead people was generally prolonged by more than 10 month. If they could continue to use Metuximab injection at that time, their lives would certainly be extended (they could not continue to use it without the approval of the State Medical Inspection Bureau).
The curative effect exceeded expectations.
According to our investigation, a small number of Likatine products (100 needles) sold by the company in 2007 are basically in existence.
Liver cancer patients use it after all kinds of methods have been tried to be ineffective and desperate, and the curative effect is super good so far.
As expected, some hospitals also found that licardin was particularly effective in treating cancer cell metastasis.
The research and development of licatin and its clinical application in the first phase were completed by the Fourth Military Medical University, and the clinical application in the second and third phases was carried out by Huashen Group.
It took more than 2 years to complete, with clinical cases 103 cases. According to the clinical trial results of licatin,
103 the symptoms of patients with primary liver cancer were obviously improved after two cycles of treatment (2 licatin).
Chart 1 clinical data of licatin
The clinical remission rate (Cr+PR) was 8.22%.
The clinical effective rate is 27.40%.
The clinical control rate (Cr+PR+Mr+SD) was 86.30%.
The median survival time was 65438 09 months.
18 months survival rate was 5 1.98%
Transfer from research report
Interventional therapy of liver cancer with radionuclide targeted drugs
Recently, Professor Zhang and Associate Professor from the Department of Gastroenterology, Shandong Provincial Hospital, with the full assistance of the Chief Professor of Nuclear Medicine, successfully implemented "guided nuclear bomb" interventional therapy for 1 patient with advanced liver cancer, and achieved remarkable results.
The patient undergoing minimally invasive interventional surgery is a middle-aged man. Two months ago, he came to the gastroenterology department of our hospital because of discomfort in his right upper abdomen. After examination, it was diagnosed as huge liver cancer, with a tumor diameter of about 10 cm, accompanied by portal vein and abdominal lymph node metastasis. The patient is in the advanced stage of liver cancer and has no chance of surgical resection. After the diagnosis, the expert group has given traditional interventional embolization treatment, and CT examination shows that there are still some residual masses. Considering the recurrence of liver cancer after interventional therapy, the expert group decided to use radionuclide targeted drugs for interventional therapy after repeated consultations in many departments. The operation was presided over by Professor Zhang and Associate Professor. After operation, a small incision of about 0.5 cm was made in the patient's groin, and the catheter was sent into the blood supply vessel of liver cancer, and then the radioisotope 13 1I labeled with liver cancer-specific antibody was injected into the liver cancer tissue through the catheter, thus specifically killing liver cancer cells. The interventional therapy was successful and the patient recovered well after operation. After discharge 15 days, he came to the hospital for a reexamination of ECT, which showed that there was still isotope drug deposition in the liver of the patient, and the interventional therapy was effective. The bad symptoms of abdominal pain and abdominal distension disappeared, and the quality of life and general condition of patients recovered well.
According to Professor Zhang, the so-called "guided nuclear bomb" interventional therapy is to use radionuclide targeted drugs to treat primary liver cancer. Taking advantage of the high affinity between targeted drugs and liver cancer cells, 13 1I was selectively introduced into liver cancer tissues, and 13 1I released high-energy β rays, which killed tumor cells for a long time in a short distance without damaging normal tissues. After treatment with this method, drugs are deposited specifically in liver cancer tissues, and there is no accumulation of radioactive drugs in other organs of the whole body, which has less side effects than traditional chemotherapy. The clinical application of radionuclide targeted drugs has filled another gap in interventional therapy of liver cancer in Shandong Province.
Professor Zhang stressed that because the incidence of liver cancer is hidden, once it is discovered, the opportunity for surgery is often lost, so the surgical resection rate of liver cancer is less than 15%, and there are problems such as high recurrence and high metastasis after operation. For patients who cannot be surgically removed, interventional chemoembolization is commonly used in clinic, that is, local injection of chemotherapy drugs into the blood supply vessels of liver cancer to embolize the blood supply vessels of liver cancer, thus killing cancer cells. But in general, the curative effect is poor and the side effects are great. At present, the natural survival time of advanced liver cancer is only 3~6 months. The successful application of this method has opened up a new way for interventional therapy of liver cancer.
(Gao Guoqi)
Application unit
1, Sichuan Cancer Hospital, Sichuan West China Hospital
2. Shandong Provincial Hospital
3. Fujian Fujian Cancer Hospital
4. Hunan Provincial People's Hospital, Hunan Cancer Hospital and Xiangya Second Hospital of Central South University, Hunan Province.
5. Shanghai Tenth People's Hospital affiliated to Tongji University, Shanghai
6. Jiangsu Jiangsu Cancer Hospital
7.Xi Tang Dou Hospital Xi First Affiliated Hospital of Jiaotong University Shaanxi Fourth Military Medical University Cancer Hospital
8. More than 80 doctors from the 458th Army of China People's Liberation Army, Guangdong.
9. China Nuclear Industry 40 1 Hospital.
10 Shengjing Hospital affiliated to Liaoning China Medical University